Method of treatment with tradipitant

A Pittan, Kawachi technology, applied in the field of NK-1 antagonists, can solve the problems of uncontrollable opioid use, personal relationship or financial negative impact

Pending Publication Date: 2021-01-12
VANDA PHARMA INC +1
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Known opioid addiction resulting in an individual's inability to control the urge to use opioids despite undesired consequences, such as negative effects on personal relationships or finances

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of treatment with tradipitant
  • Method of treatment with tradipitant
  • Method of treatment with tradipitant

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0032] A double-blind, approximately 6-week study in inpatients with a within-subjects crossover design examining the effect of maintaining oxycodone response with sendipitant compared with placebo. Study subjects included healthy adults who reported regular illicit opioid misuse and a history of intranasal opioid use without physical dependence. Participant characteristics are provided in Table 1 below.

[0033]

[0034] Subjects received placebo or sendipitant (85 mg, orally (p.o.), twice daily) on study days 3-17, with a washout period on study days 18-23, and then on study days 24-24. Placebo or sendipitant (85 mg, po., twice daily) was administered for 39 days. In this study, sendipitant / placebo administration was balanced among subjects. On Study Days 3, 18, 24, and 39, subjects participated in a challenge phase (Day 1 and Steady State) in which they received 0, 5, 10, or 20 mg intranasal (IN) oxycodone at 1-hour intervals , subsequently evaluating the analgesic ef...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed herein are methods of treating an individual who is experiencing or is at risk of experiencing an undesirable consequence of opioid use, and of treating an individual who is experiencing oris at risk of experiencing desire for opioid, and uses of an NK1 receptor antagonist Chudepitant in treating the individual.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 682,831, filed June 8, 2018, which is hereby incorporated by reference in its entirety. Background technique [0003] The present application generally relates to the use of NK-1 receptor antagonists. More specifically, the present application relates to the use of the NK-1 antagonist sendipitant in the treatment of individuals who are experiencing or are likely to experience undesired consequences of opioid use. [0004] Trandipitant (2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridyl)-1H-1,2,3-triazole -4-yl]-3-pyridyl](2-chlorophenyl)-methanone or {2-[1-(3,5-bistrifluoromethylbenzyl)-5-pyridin-4-yl- 1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone) and its pharmaceutically acceptable acid addition salts (collectively referred to herein as "Tendipitant") is known to be a highly potent, selective, centrally penet...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4439A61P25/36
CPCA61K31/4439A61P25/36A61K9/0053A61K31/444
Inventor M·H·波利梅洛伯罗斯G·P·比尔兹尼克斯S·沃尔什
Owner VANDA PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap